# Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)

> **NCT04571944** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 207 (actual)

## Conditions studied

- Delirium

## Interventions

- **DRUG:** Suvorexant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04571944
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-22
- **Primary completion:** 2022-12-23
- **Final completion:** 2022-12-23
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04571944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04571944, "Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04571944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*